Systemic amyloidosis is one of the most underdiagnosed conditions, with a median diagnostic delay of 2.7 years from symptom onset and 50% of patients seeing five or more physician types before receiving a confirmed diagnosis. Among AL amyloidosis patients, 25% mortality within six months of diagnosis due to advanced cardiac damage at presentation, while those diagnosed at early stage achieve approximately 80% five-year survival compared to less than 30% for advanced-stage disease. Autopsy studies demonstrate ATTR amyloid deposits in 20-25% of adults over age 80, and the Val122Ile variant is carried by approximately 3.4% of African Americans, representing roughly 1.5 million at-risk individuals.
AAVBC's Amyloidosis Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 subtype coding, clinical and diagnostic criteria for AL, ATTRwt, ATTRv, and AA amyloidosis, subtype differentiation, referral urgency criteria, treatment approaches by subtype, MEAT documentation standards, comorbidity screening, and goals-of-care considerations. Grounded in current ACC, AHA, and ASH guideline evidence, this guide supports consistent, individualized clinical decision-making, helping care teams document subtype complexity accurately, and coordinate care with the continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of amyloidosis — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Systemic amyloidosis is one of the most underdiagnosed conditions, with a median diagnostic delay of 2.7 years from symptom onset and 50% of patients seeing five or more physician types before receiving a confirmed diagnosis. Among AL amyloidosis patients, 25% mortality within six months of diagnosis due to advanced cardiac damage at presentation, while those diagnosed at early stage achieve approximately 80% five-year survival compared to less than 30% for advanced-stage disease. Autopsy studies demonstrate ATTR amyloid deposits in 20-25% of adults over age 80, and the Val122Ile variant is carried by approximately 3.4% of African Americans, representing roughly 1.5 million at-risk individuals.
AAVBC's Amyloidosis Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 subtype coding, clinical and diagnostic criteria for AL, ATTRwt, ATTRv, and AA amyloidosis, subtype differentiation, referral urgency criteria, treatment approaches by subtype, MEAT documentation standards, comorbidity screening, and goals-of-care considerations. Grounded in current ACC, AHA, and ASH guideline evidence, this guide supports consistent, individualized clinical decision-making, helping care teams document subtype complexity accurately, and coordinate care with the continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of amyloidosis — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
